by Raynovich Rod | Feb 25, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
2/27 Friday After a big February biotechs turned red today with major ETFs off about 1%. In light of recent M&A talk about Pharmacyclics, Inc. (PCYC) at Market Cap of $16.6B we will look at other top Mid-Cap biopharmaceutical stocks for comparison to our motif...
by Raynovich Rod | Feb 13, 2015 | Biopharmaceuticals
What will it take to drive the biotech sector to new highs? As we approach new highs for the biotech sector in 2015 here are some market trends to watch as the technicals get a little choppy. The next major indicator will be 2015 Q1 earnings. Stay tuned. Momentum of...
by Raynovich Rod | Feb 12, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Stocks Up YTD Despite Choppy Tape NASDAQ 4857.61 approaching March 10, 2000 high of 5048.62 IBB at 320.42 up 5.63% YTD and 351% over 10 Years We have updated our post from 7/1/13 on the Rayno Biopharmaceutical Portfolio with re-balancing. We are approaching...
by Raynovich Rod | Feb 4, 2015 | Life Science ETF's and Mutual Funds
Can Healthcare/Biotechnology Funds Outperform ETFs in 2015? In January of 2013 we compared three of the most liquid life science ETFs to some of the top mutual funds in the sector. Review our 2013 summary but the conclusion at that time was that ETFs provided better...
by Raynovich Rod | Feb 4, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
2/4/15 After the Bell ECB Impasse with Greece Hits Market Near Close…….. NASDAQ 4221 Down 0.19% Oil Plunges 9% to $48.74 on Inventory Rise Biotech Stocks Try To Recover But Get Hit By ECB News At Close ETFs down about 1.6% , XBI Down 1.9%, XLV down 1.24%...
by Raynovich Rod | Jan 27, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
3:55 p FEDspeak confuses markets with S&P down 1.25% Too much money around too little yield=deflation concerns. Energy takes a big hit again down 4%. Biotechs off 2% and more. ——— Update 1/28 Technology outperforming biotech in mid-day trading...
by Raynovich Rod | Jan 26, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
1/27 Sell-Off Likely Today –Durable Goods Decreased 3.4% In December Green Screen In Biotech Despite Flat Market- Mid-Day Trading 12:45 p 1/26 Most Rayno Life Science stocks were up today in a mixed market where energy is the leading sector. XBI New High at...
by Raynovich Rod | Jan 21, 2015 | Biopharmaceuticals
NASDAQ at 4667 up 0.27% XBI at $194.4 down 2.88% Clinical Stage Immuno-oncology Stocks Hit Hard Again Momentum traders took money off the table for the second time in three days. Most large cap biopharmaceutical stocks were in the red but down less than 1 %...
by Raynovich Rod | Jan 13, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
FBT up 2.4% to $108 then drifts back to 107; NASDAQ flat 4661 DOW bounced around in 425 point range. Mixed market among biotech stocks after NASDAQ and S&P sell off; momentum eases. Mid-cap immuno-oncology stocks : down AGIO, BLUE, EPZM, SGEN.; up CLVS, INCY,...
by Raynovich Rod | Jan 7, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were two...
